List of Excipients in Branded Drug FAMOTIDINE 20 MG

Generic Drugs Containing FAMOTIDINE 20 MG

Company	Ingredient	NDC	Excipient
MARKSANS PHARMA LIMITED	famotidine 20 mg	25000-124	CARNAUBA WAX
MARKSANS PHARMA LIMITED	famotidine 20 mg	25000-124	HYDROXYPROPYL CELLULOSE
MARKSANS PHARMA LIMITED	famotidine 20 mg	25000-124	HYPROMELLOSE
MARKSANS PHARMA LIMITED	famotidine 20 mg	25000-124	MAGNESIUM STEARATE
MARKSANS PHARMA LIMITED	famotidine 20 mg	25000-124	MICROCRYSTALLINE CELLULOSE 102
MARKSANS PHARMA LIMITED	famotidine 20 mg	25000-124	SACCHARIN SODIUM

What are the Most Frequently-Used Excipients in FAMOTIDINE 20 MG?

# Of NDCs	Excipient
1	CARNAUBA WAX
1	HYDROXYPROPYL CELLULOSE
1	HYPROMELLOSE
1	MAGNESIUM STEARATE
1	MICROCRYSTALLINE CELLULOSE 102
1	SACCHARIN SODIUM

Famotidine 20 mg Excipient Strategy and Commercial Opportunities

Last updated: September 8, 2026

Famotidine 20 mg is a mature, low-cost H2-receptor antagonist with limited active-ingredient patent protection and substantial generic competition. Commercial value is concentrated in formulation execution, private-label distribution, differentiated dosage forms, combination products, packaging, and regulated market access. The strongest opportunities are immediate-release tablets, chewable products, orally disintegrating formats, unit-dose packaging, and region-specific OTC or prescription products.

What is the regulatory status of famotidine 20 mg?

Famotidine 20 mg is approved in the United States as an immediate-release prescription product and is widely marketed in OTC acid-reducer products. The reference prescription product is Pepcid, originally developed by Merck. Famotidine is indicated for gastroesophageal reflux disease, duodenal ulcer, gastric ulcer, pathological hypersecretory conditions, and related acid-mediated disorders. FDA labeling includes 20 mg and 40 mg tablet strengths for several indications.[1]

Regulatory characteristic	Famotidine 20 mg
Active ingredient	Famotidine
Pharmacological class	Histamine H2-receptor antagonist
Principal dosage form	Immediate-release tablet
Prescription strength	20 mg
OTC role	Acid reducer, generally for consumers age 12 and older
FDA reference product	Pepcid tablets and related products
Biologic status	Small-molecule drug; no biosimilar pathway
Primary approval pathway for generics	ANDA
Primary commercial markets	United States, Europe, Asia, Latin America
Main competitive factor	Cost, distribution, dosage form, packaging, and brand recognition

FDA-approved generic products typically rely on the reference product’s established safety and efficacy record and demonstrate pharmaceutical equivalence and bioequivalence. Famotidine 20 mg is not a complex drug-delivery product, so development barriers are generally lower than for modified-release or locally acting gastrointestinal products.

What excipients are suitable for famotidine 20 mg tablets?

The preferred excipient platform is a conventional immediate-release tablet using a direct-compression or wet-granulation process. The formulation should prioritize rapid disintegration, consistent dissolution, low friability, physical stability, and acceptable tablet appearance.

Recommended excipient functions

Formulation function	Common excipient options	Commercial purpose
Diluent	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Controls tablet weight and compressibility
Binder	Povidone, copovidone, pregelatinized starch	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Film former	Hypromellose, polyvinyl alcohol	Protects the tablet and improves appearance
Plasticizer	Polyethylene glycol, triethyl citrate	Supports film flexibility
Opacifier	Titanium dioxide, where permitted	Provides color and light protection
Colorant	Iron oxides or approved lake colors	Product identification and branding
Sweetener	Sucralose, aspartame, acesulfame potassium, mannitol	Required for chewable or orally disintegrating products
Flavor	Mint, berry, citrus, or neutral flavor systems	Improves OTC consumer acceptance

The simplest commercial formulation is a low-weight, film-coated immediate-release tablet with microcrystalline cellulose, a superdisintegrant, magnesium stearate, and a film-coating system. A low-excipient-count formulation reduces procurement complexity and can improve manufacturing robustness.

Which excipient platform is strongest for a standard tablet?

Microcrystalline cellulose combined with crospovidone is a practical platform for direct compression. The combination provides good compactability and rapid disintegration without requiring a complex granulation process. Lactose can reduce cost but may create compatibility and moisture-management considerations, especially in formulations containing flavoring agents or hygroscopic components.

Dibasic calcium phosphate can improve tablet hardness and reduce sensitivity to compression force. It may be less suitable where a very fast disintegration profile, high drug loading, or a small tablet is required.

Magnesium stearate should be controlled carefully. Excessive concentration or over-lubrication can slow wetting and dissolution. Sodium stearyl fumarate can be evaluated when a formulation requires lower hydrophobicity or improved processing performance.

What excipients are best for famotidine 20 mg chewable tablets?

Chewable famotidine 20 mg products create a stronger commercial differentiation opportunity than conventional tablets. The formulation must address taste, mouthfeel, tablet strength, chewability, and flavor persistence.

Mannitol is often useful as a principal diluent because it provides a cooling mouthfeel and lower hygroscopicity than some alternatives. Sorbitol can improve sweetness and mouthfeel but may increase moisture sensitivity and gastrointestinal tolerability concerns at higher levels. Crospovidone or low-substituted hydroxypropyl cellulose can support tablet breakup without producing excessive grittiness.

A chewable formulation may include:

• Mannitol or isomalt as the principal bulk sweetener
• Sucralose or acesulfame potassium for high-intensity sweetness
• Crospovidone or croscarmellose sodium as disintegrant
• Colloidal silicon dioxide for flow control
• Magnesium stearate or sodium stearyl fumarate as lubricant
• Mint, berry, or citrus flavor
• A taste-masking system, if required

Famotidine has a potentially unpleasant active-ingredient taste. Flavor alone may not provide sufficient masking at a 20 mg dose. Polymer coating, ion-exchange resins, lipid-based barriers, or multiparticulate taste-masking systems can improve palatability, although these options increase process complexity and regulatory documentation.

What formulation opportunities exist for orally disintegrating famotidine 20 mg?

Orally disintegrating tablets can target consumers who have difficulty swallowing conventional tablets. The main technical challenge is balancing rapid disintegration with mechanical strength during packaging, transportation, and consumer handling.

A viable orally disintegrating formulation may use:

• Mannitol for mouthfeel and bulk
• Crospovidone or a highly porous disintegrant
• Low-dose binder
• Flavor and sweetener
• Low-moisture film or blister packaging
• Direct compression or specialized molding technology

Blister packaging is generally more suitable than standard high-density polyethylene bottles when the formulation is moisture-sensitive or mechanically fragile. However, bottle packaging may offer lower cost and easier high-volume filling. The commercial choice depends on stability data, target price, and retail-channel expectations.

What formulation patents protect famotidine 20 mg products?

The foundational famotidine compound patents are expired. Famotidine’s core U.S. patent estate dates to the original development period, including U.S. Patent No. 4,496,737, which covered related guanidinothiazole compounds and expired long ago under the applicable patent term.[2]

Current commercial protection does not generally come from the active ingredient. Potentially relevant rights can instead involve:

• Chewable compositions
• Taste-masked formulations
• Orally disintegrating tablets
• Combination products containing antacids
• Specific coating systems
• Manufacturing processes
• Packaging configurations
• Method-of-use claims
• Brand-specific trade dress and trademarks

These rights must be assessed product by product. A formulation patent covering a particular excipient ratio or manufacturing process does not necessarily prevent development of a non-infringing conventional tablet.

When does famotidine 20 mg lose exclusivity?

Famotidine’s principal small-molecule exclusivity expired many years ago. Generic manufacturers can generally pursue ANDA approval for conventional famotidine tablets without confronting an unexpired composition-of-matter patent.

Exclusivity category	Status
Compound patent	Expired
Original prescription market exclusivity	Expired
Conventional tablet formulation exclusivity	Generally expired or commercially immaterial
Pediatric exclusivity	No current commercial relevance
Orphan exclusivity	Not applicable to the mainstream 20 mg product
Biologic exclusivity	Not applicable
OTC monograph protection	Regulatory pathway, not product-level patent exclusivity

The principal barriers are therefore regulatory compliance, manufacturing cost, supply reliability, retail access, and brand positioning rather than basic patent exclusivity.

What is the Orange Book status of famotidine 20 mg?

Famotidine prescription tablets and approved generic equivalents are listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. Orange Book status is product-specific. Each approved strength, dosage form, and applicant has its own listing and therapeutic-equivalence designation.[3]

For a conventional famotidine 20 mg tablet, the relevant regulatory objectives are:

1. Pharmaceutical equivalence to the reference product.
2. Demonstrated bioequivalence.
3. Conformance with current good manufacturing practice.
4. Approved labeling and indications.
5. Appropriate stability and dissolution data.
6. Accurate inactive-ingredient disclosure.

Because the compound is old and widely genericized, Paragraph IV litigation is not ordinarily the central market issue for standard famotidine 20 mg tablets. Paragraph IV risk can become relevant where a sponsor seeks approval for a newer, separately patented dosage form or combination product.

Which companies compete in the famotidine 20 mg market?

Competition exists across branded, generic, private-label, and combination-product segments.

Prescription and generic competition

Major generic manufacturers and distributors have historically marketed famotidine tablets, including companies such as Teva, Apotex, Mylan or Viatris, Sandoz, Dr. Reddy’s Laboratories, and various regional suppliers. Product availability changes by country, supplier, and procurement channel.

OTC competition

The main OTC competitors include:

• Famotidine brands and store brands
• Omeprazole and other proton-pump inhibitors
• Cimetidine
• Calcium carbonate antacids
• Combination products containing famotidine and antacids

Famotidine has a shorter-acting positioning than proton-pump inhibitors and is often marketed for rapid or on-demand acid relief. That positioning supports smaller package sizes, travel packs, and episodic-use products.

What commercial opportunities exist for famotidine 20 mg?

Private-label OTC products

Private-label famotidine 20 mg tablets are the most accessible commercial opportunity. Retailers can compete on price while using essentially conventional manufacturing technology. Differentiation can come from:

• 15-, 30-, 50-, or 90-count packages
• Store-brand packaging
• Club-store multi-packs
• Travel-size packs
• Value bottles
• Two-strength portfolios with 10 mg and 20 mg products

Chewable and orally disintegrating formats

These products can support higher margins than standard tablets if taste, stability, and packaging are well controlled. They can target consumers who dislike swallowing tablets and consumers seeking convenient on-demand dosing.

Combination antacid products

Combination products can offer rapid neutralization from an antacid with longer acid suppression from famotidine. The commercial precedent is Pepcid Complete, which combines famotidine with calcium carbonate and magnesium hydroxide. A 20 mg famotidine combination would require careful regulatory and labeling analysis because marketed combination strengths and dosing instructions differ from single-ingredient products.[4]

Institutional and contract-manufacturing supply

Hospitals, pharmacy chains, wholesalers, and government procurement programs purchase generic famotidine based on price, supply continuity, quality history, and validated manufacturing capacity. A supplier with dual-source API procurement, domestic packaging, and reliable release testing can compete even without formulation novelty.

International markets

Famotidine 20 mg has opportunities in countries where H2-receptor antagonists remain commonly prescribed or where OTC access is developing. Market entry requires country-specific review of:

• Prescription versus OTC classification
• Approved indications
• Reference-product requirements
• Local bioequivalence rules
• Stability-zone requirements
• Label language
• Import and serialization rules
• Local pharmacovigilance obligations

What manufacturing and IP barriers affect famotidine 20 mg?

Manufacturing barriers are moderate rather than high. API availability, analytical method validation, dissolution consistency, and supply-chain qualification are more important than novel drug-delivery technology.

The main technical risks are:

• API particle-size variation
• Content-uniformity failures at relatively low tablet weight
• Blend segregation
• Lubricant over-mixing
• Slow dissolution from excessive hydrophobic excipients
• Flavor or sweetener instability
• Moisture uptake in chewable and orally disintegrating formats
• Tablet capping or friability
• Packaging-related stability failures

The core IP risk is low for a conventional tablet. Risk increases for a differentiated product using patented taste-masking technology, a patented combination, or a formulation with narrow claim scope around excipient ratios.

How strong is the patent estate for famotidine 20 mg?

Estate component	Strength
Core compound patent	None remaining
Conventional immediate-release tablet	Low
Standard film coating	Low
Chewable formulation	Potentially moderate, claim-specific
Orally disintegrating formulation	Potentially moderate, claim-specific
Antacid combination	Potentially moderate, product-specific
Manufacturing process	Low to moderate
Trademark and trade dress	Potentially meaningful for branded OTC products
Regulatory exclusivity	Low for standard generic tablets

The estate is weak for conventional famotidine 20 mg tablets. Commercial defensibility depends on cost, channel access, consumer recognition, packaging, and execution.

What generic launch scenarios exist for famotidine 20 mg?

A new entrant can pursue four practical launch models:

Launch model	Investment	Differentiation	Margin potential
Standard prescription tablet	Low	Low	Low
Private-label OTC tablet	Low to moderate	Moderate through packaging and channel	Moderate
Chewable tablet	Moderate	High	Moderate to high
Combination antacid product	Moderate to high	High	High, with greater regulatory complexity

The lowest-risk route is a conventional immediate-release tablet supported by a competitive ANDA or applicable OTC pathway. The highest commercial upside is in a palatable, convenient dosage form with strong retail placement, although that route adds formulation, stability, labeling, and manufacturing risk.

Key Takeaways

• Famotidine 20 mg is a mature small-molecule product with expired core patent protection.
• Conventional immediate-release tablets have low technical and IP barriers.
• Microcrystalline cellulose, crospovidone, a controlled lubricant level, and standard film coating provide a practical generic platform.
• Chewable and orally disintegrating products offer greater differentiation than standard tablets.
• Taste masking, moisture control, and packaging are the main formulation issues for differentiated products.
• Combination products with calcium carbonate and magnesium hydroxide offer commercial potential but require product-specific regulatory analysis.
• The principal competitive advantages are manufacturing cost, supply reliability, private-label access, dosage-form convenience, and packaging.
• Biosimilar risk does not apply because famotidine is a small-molecule drug.
• Paragraph IV exposure is limited for conventional famotidine 20 mg tablets but can arise around newer formulations or combinations.
• The strongest opportunity is a low-cost OTC or private-label product with a differentiated package size, chewable format, or orally disintegrating presentation.

FAQs

Is famotidine 20 mg suitable for direct-compression manufacturing?

Yes. A direct-compression platform using microcrystalline cellulose, a superdisintegrant, glidant, and controlled lubricant level is suitable when powder flow and content uniformity are validated.

Can a new company patent a famotidine 20 mg tablet?

A new company is unlikely to obtain broad patent protection for the active ingredient or a conventional tablet. Patentability may exist for a genuinely novel taste-masking system, combination, manufacturing process, or dosage-form architecture.

Which package is best for famotidine 20 mg?

High-density polyethylene bottles are cost-efficient for standard tablets. Unit-dose blister packaging is better suited to travel products, moisture-sensitive formulations, and premium OTC positioning.

Is famotidine 20 mg a biosimilar opportunity?

No. Famotidine is a chemically synthesized small molecule. Development generally follows the generic-drug pathway rather than the biosimilar pathway.

Does a famotidine 20 mg product need a novel excipient?

No. Conventional compendial excipients are sufficient for standard immediate-release tablets. Novel excipients are unnecessary unless the sponsor pursues a specialized delivery or taste-masking system.

References

1. U.S. Food and Drug Administration. (2023). Pepcid (famotidine) tablets: Prescribing information. FDA/DailyMed.

2. United States Patent and Trademark Office. (1985). U.S. Patent No. 4,496,737: Guanidinothiazole compounds. U.S. Department of Commerce.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2023). Pepcid Complete: Drug facts and labeling. FDA/DailyMed.

5. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. ICH.

6. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.